Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111096 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT02111096: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT02111096 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02111096, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).
Primary Outcome
The hepatic fat fraction (HFF) was calculated by a core imaging laboratory from noncontrast magnetic resonance imaging (MRI) of the liver. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, country, baseline HbA1c stratum (\<=8.0%, \>8.0%), visit, baseline score, and treatment-by-visit.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Sulfonylurea
- DRUG LY2409021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT02111096 stopped before completion
NCT02111096 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02111096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02111096 about?
NCT02111096 is a clinical study titled "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus". The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).
What is the current status of trial NCT02111096?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2014-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02111096?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Sitagliptin (DRUG), Sulfonylurea (DRUG), LY2409021 (DRUG).
Who is sponsoring clinical trial NCT02111096?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02111096's enrollment target sits among peer trials
174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia